StockData
Sonoma Pharmaceuticals, Inc. logo

Sonoma Pharmaceuticals, Inc. (SNOA) shareholders

SNOANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends March 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3082% below fair value
$0.83−0.05 (-5.21%)

Close on Nov 17, 2026Market cap $3.99MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
2.3%
0M of 5M shares
Institutional holders
14
4 new, 6 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of SNOAValueChange% of portfolio
Renaissance Technologies LLC40,4680.85%$49.78KNew0.00%
Geode Capital Management, LLC26,7870.56%$32.95K+6,8460.00%
Vanguard Capital Management LLC18,7870.39%$23.11K–0.00%
McKinley Carter Wealth Services, Inc.11,1930.23%$13.77K–0.00%
UBS Group AG7,8080.16%$9.60K+7,8020.00%
Global Retirement Partners, LLC2,5480.05%$3.13KNew0.00%
Morgan Stanley2,0000.04%$2.46K−40.00%
Osaic Holdings, Inc.5000.01%$615–0.00%
Barclays PLC4590.01%$565New0.00%
BlackRock, Inc.1130.00%$139–0.00%
Vanguard Fiduciary Trust Co1000.00%$123–0.00%
Harbour Investments, Inc.150.00%$18New0.00%
Quaker Wealth Management, LLC30.00%$4–0.00%
Danske Bank A/S10.00%$1–0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026140M2.3%4 / 21 / 60M0M
Q1 2026170M1.4%4 / 41 / 10M0M
Q4 2025160M2.3%2 / 35 / 60M0M
Q3 2025200M1.2%8 / 21 / 20M0M
Q2 2025140M1.8%4 / 32 / 20M0M
Q1 2025120M0.7%3 / 12 / 00M0M
Q4 202490M0.4%0 / 22 / 50M0M
Q3 2024140M0.6%14 / 00 / 10M0M
Q2 202410M0.0%1 / 00 / 00M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

4 funds held SNOA in Q2 2026, 50% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of SNOAValue% of fundAs of
Vanguard Extended Market Index Fund18,7870.39%$23.11K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund13,9340.29%$15.88K0.00%May 31, 2026
Fidelity Total Market Index Fund2,5280.05%$2.88K0.00%May 31, 2026
Fidelity Series Total Market Index Fund2,3140.05%$2.64K0.00%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Poggetto John DalController15,0000.31%Jul 9, 2026
Amy Moss TromblyChief Executive Officer153,5863.21%Jul 9, 2026
Jerome J. DvonchChief Financial Officer84,5951.77%Jul 9, 2026
Bruce ThorntonExecutive VP and COO154,4113.22%Jun 20, 2025
Vanessa JacobyDirector––Jul 9, 2026
John McLaughlinDirector48,7281.02%Jul 9, 2026
Philippe WeigerstorferDirector22,5000.47%Jul 9, 2026
Jay E. BirnbaumDirector51,6591.08%Jan 2, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Jerome J. Dvonch
Chief Financial Officer
Jun 20, 2024Award+53,586––84,595
Poggetto John Dal
Controller
Jun 20, 2024Award+15,000––15,000
Bruce Thornton
Executive Vice President
Jun 20, 2024Award+53,586––154,411
Amy Moss Trombly
Chief Executive Officer
Jun 20, 2024Award+53,586––153,586
Amy Moss Trombly
Chief Executive Officer
Jun 30, 2023Award+100,000––213,648
Bruce Thornton
Executive Vice President
Jun 30, 2023Award+100,000––216,781
Poggetto John Dal
Chief Financial Officer
Apr 23, 2020Award+3,086––3,201
Robert Grant Edwards
Chief Financial Officer
Apr 23, 2020Award+2,609––2,609
John McLaughlin
Director
May 30, 2018Award+1,781––48,728
Russell Joseph Harrison
Director
May 30, 2018Award+1,538––46,520
Jay E. Birnbaum
Director
May 30, 2018Award+1,052––51,659
Robert E. Miller
Chief Financial Officer
Mar 13, 2018Buy+1,200$4.10$4.92K18,868
Robert E. Miller
Chief Financial Officer
Mar 12, 2018Buy+1,200$4.03$4.84K17,668
Robert E. Miller
Chief Financial Officer
Mar 12, 2018Buy+1,200$4.03$4.84K16,468
Robert E. Miller
Chief Financial Officer
Mar 9, 2018Buy+1,200$3.90$4.68K15,268
James J. Schutz
Chief Executive Officer, Director
Mar 8, 2018Buy+2,473$3.99$9.87K35,858
Sharon Barbari
Director
Mar 1, 2018Award+1,424––43,417
Jay E. Birnbaum
Director
Mar 1, 2018Award+1,157––50,607
John McLaughlin
Director
Mar 1, 2018Award+1,958––46,947
Russell Joseph Harrison
Director
Mar 1, 2018Award+1,691––44,982
John McLaughlin
Director
Jan 2, 2018Award+17,211––44,989
James J. Schutz
Chief Executive Officer, Director
Jan 2, 2018Award+17,211––33,385
Jay E. Birnbaum
Director
Jan 2, 2018Award+25,817––49,450
Sharon Barbari
Director
Jan 2, 2018Award+17,211––41,993
Russell Joseph Harrison
Director
Jan 2, 2018Award+17,211––43,291
James J. Schutz
Chief Executive Officer, Director
Nov 30, 2017Buy+345$4.95$1.71K16,174
John McLaughlin
Director
Nov 29, 2017Award+14,317––27,778
Sharon Barbari
Director
Nov 29, 2017Award+13,944––24,782
Russell Joseph Harrison
Director
Nov 29, 2017Award+14,130––26,080
Jay E. Birnbaum
Director
Nov 29, 2017Award+13,757––23,633
Robert E. Miller
Chief Financial Officer
Nov 29, 2017Buy+1,290$5.02$6.48K14,068
Robert E. Miller
Chief Financial Officer
Nov 29, 2017Buy+500$5.03$2.52K12,778
James J. Schutz
Chief Executive Officer, Director
Nov 29, 2017Buy+400$5.03$2.01K15,829
James J. Schutz
Chief Executive Officer, Director
Nov 24, 2017Buy+254$5.05$1.28K15,429
Robert E. Miller
Chief Financial Officer
Nov 21, 2017Buy+500$5.04$2.52K12,278
Robert E. Miller
Chief Financial Officer
Nov 21, 2017Buy+1,500$5.03$7.55K11,778
John McLaughlin
Director
Aug 29, 2017Award+1,210––13,471
Jay E. Birnbaum
Director
Aug 29, 2017Award+715––9,876
Sharon Barbari
Director
Aug 29, 2017Award+880––10,838
Russell Joseph Harrison
Director
Aug 29, 2017Award+1,045––11,950
Robert E. Miller
Chief Financial Officer
Aug 10, 2017Buy+2,264$5.30$12.00K10,728
Marc Umscheid
Chief Strategy/Mkt Officer
Aug 10, 2017Buy+600$5.31$3.19K3,392
James J. Schutz
Chief Executive Officer, Director
Aug 10, 2017Buy+929$5.46$5.07K15,175
Marc Umscheid
Chief Strategy/Mkt Officer
Jun 29, 2017Award+2,042––2,792
Robert E. Miller
Chief Financial Officer
Jun 29, 2017Award+4,124––20,088
Robert Allen Northey
Exe. VP of Research and Dev.
Jun 29, 2017Award+3,404––8,082
James J. Schutz
Chief Executive Officer, Director
Jun 29, 2017Award+2,406––14,246
John McLaughlin
Director
May 30, 2017Award+1,036––12,261
Sharon Barbari
Director
May 30, 2017Award+754––9,958
Russell Joseph Harrison
Director
May 30, 2017Award+895––10,905
Jay E. Birnbaum
Director
May 30, 2017Award+612––9,161
Robert E. Miller
Chief Financial Officer
Mar 9, 2017Buy+250$7.14$1.79K8,464
Robert E. Miller
Chief Financial Officer
Mar 9, 2017Buy+250$6.97$1.74K7,964
Robert E. Miller
Chief Financial Officer
Mar 9, 2017Buy+250$6.96$1.74K8,214
Robert E. Miller
Chief Financial Officer
Mar 8, 2017Buy+750$6.97$5.23K7,714
Robert E. Miller
Chief Financial Officer
Mar 8, 2017Buy+250$6.81$1.70K6,964
Marc Umscheid
Chief Strategy/Mkt Officer
Mar 6, 2017Buy+750$6.82$5.12K750
James J. Schutz
Chief Executive Officer, Director
Mar 3, 2017Buy+104$6.75$70211,840
James J. Schutz
Chief Executive Officer, Director
Mar 3, 2017Buy+696$6.78$4.72K11,736
Jay E. Birnbaum
Director
Mar 1, 2017Award+577––8,549

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
1.57%
0M shares short
Days to cover
1.7
At 0M shares a day
Change since last report
-38.7%
From 0M shares
Short volume, 20 days
18.2%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Sonoma Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,500 shares on Aug 21, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Gottfurcht Grant
10% Stockholder
Jan 3, 202586,111$232.50KJan 3, 2025Open Market
Gottfurcht Grant
10% Stockholder
Jan 3, 202530,000$80.68KJan 2, 2025Open Market
Gottfurcht Grant
10% Stockholder
Jan 3, 202517,806$48.56KDec 31, 2024Open Market
Gottfurcht Grant
Open Market
Jan 2, 202530,000$80.68KJan 2, 2025Open Market
Gottfurcht Grant
Open Market Purchase
Jan 2, 202517,806$48.56KDec 31, 2024Open Market
Gottfurcht Grant
10% Stockholder
Dec 26, 2024221,375$56.46KAug 9, 2024Open Market

See a number that looks wrong?